Journal of Clinical Endocrinology & Metabolism, Vol 78, 197-204, Copyright © 1994 by Endocrine Society

ARTICLES

Pharmacokinetics of 17 beta-dihydroequilin sulfate and 17 beta- dihydroequilin in normal postmenopausal women

BR Bhavnani and A Cecutti
Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada.

The MCRs of 17 beta-dihydroequilin sulfate and 17 beta-dihydroequilin were determined in normal postmenopausal women by single iv injection of either 17 beta-[3H]dihydroequilin sulfate ([3H]17 beta-EqS) or 17 beta-[3H]dihydroequilin ([3H]17 beta-Eq). After the administration of [3H]17 beta-EqS, blood was drawn at various time intervals, and the plasma obtained was fractionated into the unconjugated, sulfate, and glucuronide fractions. The bulk of radioactivity was present in the sulfate fraction, and from this [3H]17 beta-EqS, [3H]equilin sulfate, [3H]equilenin sulfate, and 17 beta-[3H]dihydroequilenin sulfate were isolated and purified, and their concentrations were measured. The disappearance of [3H]17 beta-EqS from plasma can be described as a function of two exponentials. The half-life of the initial fast component was 5 +/- 0.2 min; this component represents the distribution and transfer from a space, with a mean volume (V1) of 6 +/- 0.5 L. The value for the rate constant (k) of total removal from this space was 300 +/- 20 U/day, of which 35 +/- 2% was irreversible. The mean half- life of the slower component of 17 beta-EqS was 147 +/- 15 min, and the mean MCR was 376 +/- 93 L/day.m2. Similarly, after the administration of [3H]17 beta-Eq, the disappearance of radioactivity as 17 beta-Eq from plasma also had two components. The half-lives of the fast and slow component were 5.5 +/- 0.8 and 45 +/- 2.0 min, respectively. The MCR of 17 beta-Eq was 1252 +/- 103 L/day.m2. From both series of experiments, unconjugated and sulfate-conjugated equilin, equilenin, and 17 beta-dihydroequilenin were isolated and purified, and their concentrations were measured. No 17 alpha-reduced metabolites were detected. These results indicate that 17 beta-EqS is cleared twice as fast as equilin sulfate (MCR, 176 L/day.m2), whereas the more potent estrogen 17 beta-Eq is cleared 2 times slower than equilin. The slower elimination and greater estrogenic activity of 17 beta-Eq support the hypothesis that the major in vivo activity of equilin sulfate present in conjugated equine estrogen preparations is expressed via its metabolites 17 beta-EqS and 17 beta-Eq.

This article has been cited by other articles:

				B. R. Bhavnani, A. Cecutti, and A. Gerulath Pharmacokinetics of 17{beta}-Dihydroequilin Sulfate in Normal Postmenopausal Women Under Steady State Conditions Reproductive Sciences, March 1, 2002; 9(2): 102 - 110. [Abstract] [PDF]

				B. R. Bhavnani, J. A. Nisker, J. Martin, F. Aletebi, L. Watson, and J. K. Milne Comparison of Pharmacokinetics of a Conjugated Equine Estrogen Preparation (Premarin) and a Synthetic Mixture of Estrogens (C.E.S.) in Postmenopausal Women Reproductive Sciences, May 1, 2000; 7(3): 175 - 183. [Abstract] [PDF]

				T. J. Puranen, R. M. Kurkela, J. T. Lakkakorpi, M. H. Poutanen, P. V. Itäranta, J. P. J. Melis, D. Ghosh, R. K. Vihko, and P. T. Vihko Characterization of Molecular and Catalytic Properties of Intact and Truncated Human 17{beta}-Hydroxysteroid Dehydrogenase Type 2 Enzymes: Intracellular Localization of the Wild-Type Enzyme in the Endoplasmic Reticulum Endocrinology, July 1, 1999; 140(7): 3334 - 3341. [Abstract] [Full Text]

				L. A. Paige, D. J. Christensen, H. Gron, J. D. Norris, E. B. Gottlin, K. M. Padilla, C.-y. Chang, L. M. Ballas, P. T. Hamilton, D. P. McDonnell, et al. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha  and ER beta PNAS, March 30, 1999; 96(7): 3999 - 4004. [Abstract] [Full Text] [PDF]